Regentis Biomaterials (RGNT) awards director options and low-cost warrants
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Regentis Biomaterials director Jeff Dykan reported equity compensation consisting of 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each for ordinary shares. The options vest quarterly over three years until fully vested on May 28, 2029, while the warrants are currently exercisable for a three-year term through February 23, 2029. Both awards were approved by the board and became effective after shareholder approval on July 9, 2026.
Positive
- None.
Negative
- None.
Insider Trade Summary
2 transactions reported
Mixed
2 txns
Insider
Dykan Jeff
Role
Director
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Warrants to purchase ordinary shares | 12,500 | $0.00 | -- |
| Grant/Award | Employee Stock Option (Right to Buy) | 24,826 | $0.00 | -- |
Holdings After Transaction:
Warrants to purchase ordinary shares — 12,500 shares (Direct);
Employee Stock Option (Right to Buy) — 24,826 shares (Direct)
Footnotes (1)
- This warrant was approved by the Board of Directors of the Issuer on February 23, 2026, subject to shareholder approval, which was obtained on July 9, 2026. The warrants are currently exercisable and have a three year term. This option grant was approved by the Board of Directors of the Issuer on May 28, 2026, subject to shareholder approval, which was obtained on July 9, 2026. This options grant shall vest on a quarterly basis, with one-twelfth (1/12) vesting on August 28, 2026, and an additional one-twelfth vesting on last day of each subsequent three-month period thereafter, subject to the Reporting Person's continuous employment through the applicable vesting date, until the options fully vest on the third anniversary of the grant date, or May 28, 2029. To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued to an employee in connection with the Issuer's 2024 Share Option Plan must be registered in the name of a trustee.
Key Figures
Employee stock options granted: 24,826 options
Option exercise price: $2.1600 per share
Option expiration date: May 28, 2036
+4 more
7 metrics
Employee stock options granted
24,826 options
Derivative grant to director Jeff Dykan on July 9, 2026
Option exercise price
$2.1600 per share
Exercise price of 24,826 employee stock options over ordinary shares
Option expiration date
May 28, 2036
Expiration of employee stock options granted to Jeff Dykan
Warrants granted
12,500 warrants
Derivative warrant grant to purchase ordinary shares on July 9, 2026
Warrant exercise price
$0.0030 per share
Exercise price of 12,500 warrants over ordinary shares
Warrant expiration date
February 23, 2029
End of three-year term for 12,500 warrants
Option vesting period
3 years
Options vest quarterly until fully vested on May 28, 2029
Key Terms
Employee Stock Option (Right to Buy), Section 102 of the Israeli Tax Ordinance, 2024 Share Option Plan, vest on a quarterly basis
4 terms
Employee Stock Option (Right to Buy) financial
"Security title is listed as Employee Stock Option (Right to Buy) for 24,826 shares"
Section 102 of the Israeli Tax Ordinance regulatory
"To qualify for certain tax benefits under Section 102 of the Israeli Tax Ordinance"
vest on a quarterly basis financial
"This options grant shall vest on a quarterly basis, with one-twelfth vesting on August 28, 2026"
FAQ
What equity awards did Regentis Biomaterials (RGNT) grant to director Jeff Dykan?
Regentis Biomaterials granted Jeff Dykan 24,826 employee stock options with a $2.1600 exercise price and 12,500 warrants with a $0.0030 exercise price, each over ordinary shares, as part of his reported equity compensation.
What are the vesting terms of Jeff Dykan’s stock options at Regentis Biomaterials (RGNT)?
The options granted to Jeff Dykan vest on a quarterly basis over three years. One-twelfth vests on August 28, 2026, with additional one-twelfth tranches vesting every three months until full vesting on May 28, 2029, subject to continuous service.
When do Jeff Dykan’s warrants and options at Regentis Biomaterials (RGNT) expire?
Jeff Dykan’s warrants expire on February 23, 2029, and his stock options expire on May 28, 2036. The warrants have a three-year term and are currently exercisable, while the options provide a longer-term incentive horizon.
What approvals were required for the RGNT equity awards reported for Jeff Dykan?
Both the warrants and stock options were approved by the board and made effective only after shareholder approval on July 9, 2026. The warrants were originally approved on February 23, 2026, and the options on May 28, 2026.
How does Israeli tax law affect Jeff Dykan’s RGNT equity awards?
To qualify for tax benefits under Section 102 of the Israeli Tax Ordinance, securities issued under Regentis Biomaterials’ 2024 Share Option Plan must be registered in the name of a trustee, affecting how the awards are held for tax purposes.
Are Jeff Dykan’s warrants at Regentis Biomaterials (RGNT) currently exercisable?
Yes. The filing states that the warrants are currently exercisable and have a three-year term. They relate to 12,500 ordinary shares at a $0.0030 exercise price and expire on February 23, 2029.